The drugmaker said data shows sufficient evidence that both their monotherapy and combination therapy antibody drugs may be effective to treat the virus.
The combination therapy reduced the viral load, symptoms and number of hospitalizations in a phase 2 trial and saw no serious adverse effects.
The monotherapy had some adverse effects, including infusion reactions, that Eli Lilly said were generally mild. Two patients experienced serious infusion reactions, but all patients recovered.
Eli Lilly said it will publish the data in peer-reviewed journals as soon as possible.
The drugmaker said it’s already manufactured hundreds of thousands of doses of the drugs and has submitted an EUA request for its monotherapy for use in higher-risk patients recently diagnosed with mild to moderate COVID-19. It expects to submit an EUA request for the combination therapy in November.
Read the full news release here.
More articles on pharmacy:
Law regulating PBMs to be reviewed by Supreme Court
White House reverses course, endorses FDA’s COVID-19 vaccine authorization guidelines
Moderna COVID-19 vaccine trial slowed; too few minority participants
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
